Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris 03:12:59 2024-04-23 am EDT 5-day change 1st Jan Change
89.14 EUR +1.10% Intraday chart for Sanofi +2.64% -0.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sanofi: positive phase III data in IPT CF
Sanofi Reports Positive Results from Phase 3 Trial of Rilzabrutinib for Immune Thrombocytopenia MT
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial DJ
Sanofi Reaches $100 Million Settlement for US Lawsuits Over Zantac Cancer Claims MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations MT
Top Midday Stories: Verizon Shares Down, Truist Shares Up Post Earnings; CNH Industrial Names New Chief Executive; Tesla Dissolves Newly Created Marketing Team MT
Sanofi to Pay More Than $100 Million to Settle 4,000 Suits Alleging Zantac Causes Cancer MT
Sanofi Reportedly Agrees to Settle Zantac Cancer Lawsuits for More Than $100 Million MT
SANOFI : Gets a Buy rating from UBS ZD
Sector Update: Health Care Stocks Rise Friday Afternoon MT
Global markets live: P&G, Amex, Blackstone, Apple, Tesla... Our Logo
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Sector Update: Health Care MT
Sanofi Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely MT
Sanofi Reportedly Planning to Restructure US Commercial Operations for Vaccines; Job Losses Likely MT
Sanofi to overhaul US operations of vaccines, cut jobs RE
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
SANOFI : JP Morgan reiterates its Neutral rating ZD
Sanofi Announces Quebec's INESSS Recommends BEYFORTUS® for Prevention of RSV for All Infants 8 Months of Age and Younger CI
IGM Biosciences, Sanofi Narrow Partnership to Focus on Potential Immunology and Inflamation Targets MT
BeiGene to Award Shares Worth $15 Million to 11 Directors MT
Sanofi's Frexalimab Reduces Disease Activity in Multiple Sclerosis Patients in Phase 2 Trial MT
Sanofi: new positive phase II results in MS CF
IDT Australia Signs Master Service Agreement with Sanofi MT
Chart Sanofi
More charts
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
88.17 EUR
Average target price
107.5 EUR
Spread / Average Target
+21.92%
Consensus
  1. Stock Market
  2. Equities
  3. SAN Stock
  4. News Sanofi
  5. Sanofi : Plans $476 Million Annual Investments In New mRNA Vaccine Center